インデックス付き
  • Jゲートを開く
  • Genamics JournalSeek
  • アカデミックキー
  • ジャーナル目次
  • 研究聖書
  • 中国国家知識基盤 (CNKI)
  • シマゴ
  • ウルリッヒの定期刊行物ディレクトリ
  • 電子ジャーナルライブラリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • SWBオンラインカタログ
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ミアル
  • 科学インデックスサービス (SIS)
  • ユーロパブ
  • Google スカラー
このページをシェアする
ジャーナルチラシ
Flyer image

概要

Acquiring to Cancer Stem-Like Cells with Targeted Nano Medicine has Potential for Use in Medicine

Vamshi P*

Multiple drug resistance (MDR) to chemotherapeutic medicines, both inherited and acquired, is a significant barrier to effective cancer treatment. P-glycoprotein and multidrug-resistance-associated proteins are examples of the ATP Binding Cassettes (ABC) transporter super family, which function as extrusion pumps. Blocking the pump proteins physically can tilt the balance between drug input and efflux toward an accumulation of the drug inside the cell, which eventually leads to cell death [1]. This is one of the most effective ways to control the active drug's efflux from the cells. Drugs approved for uses other than treating cancer included MDR modulators, commonly referred to as Chemosensitizers. However, their clinical use is limited by their toxicity, side effects, and low solubility at levels needed to reverse MDR. Prior studies have demonstrated that medications from the selective serotonin reuptake inhibitor (SSRI) family, which are routinely utilised as antidepressants, can function as efficient Chemosensitizers both in vitro and in vivo in tumor-bearing animal models [2]. In this study, we investigated the potential of sertraline (Zoloft®), a member of the SSRI family of drugs, to act as an MDR modulator. Using another FDA-approved medication in combination with sertraline.

Keywords Chemosensitizers; Drug Resistance

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません